Evolving Approaches to Alzheimer’s Disease
Finding the Way Forward
The future of anti-amyloid trials.
Aisen PS, Cummings J, Doody R, et al. J Prev Alzheimers Dis. 2020;7(3):146-151.
2021 Alzheimer’s disease facts and figures.
Alzheimer’s Association.
Neuropathological stageing of Alzheimer-related changes.
Braak H, Braak E. Acta Neuropathol. 1991;82(4):239-259.
EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease.
Budd Haeberlein S, von Hehn C, Tian Y, et al. Presented at: 12th Clinical Trials on Alzheimer’s Disease; December 4-7, 2019; San Diego, CA.
Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment.
Chandra A, Dervenoulas G, Politis M. J Neurol. 2019;266(6):1293-1302.
Biomarkers for Alzheimer's disease. Where we stand and where we are headed.
Chrem Méndez P, Surace E, Bérgamo Y, et al. Medicina (B Aires). 2019;79(Spec 6/1):546-551.
Imaging and molecular mechanisms of Alzheimer's disease: a review.
Femminella GD, Thayanandan T, Calsolaro V, et al. Int J Mol Sci. 2018;19(12):3702.
Costly new Alzheimer disease medications on the horizon—financing alternatives for Medicare.
Fleming WK, Brown CR, Shrank WH. JAMA Health Forum. 2020;1(9):e201148.
Pharmacotherapy of Alzheimer's disease: seeking clarity in a time of uncertainty.
Husna Ibrahim N, Yahaya MF, Mohamed W, et al. Front Pharmacol. 2020;11:261.
A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers.
Jack CR Jr, Bennett DA, Blennow K, et al. Neurology. 2016;87(5):539-547.
The diagnosis and management of mild cognitive impairment: a clinical review.
Langa KM, Levine DA. JAMA. 2014;312(23):2551-2561.
Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older.
Larson EB, Wang L, Bowen JD, et al. Ann Intern Med. 2006;144(2):73-81.
Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies.
Li JQ, Tan L, Wang HF, et al. J Neurol Neurosurg Psychiatry. 2016;87(5):476-484.
Donanemab in early Alzheimer's disease.
Mintun MA, Lo AC, Duggan Evans C, et al. N Engl J Med. 2021. Epub ahead of print.
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease.
Panza F, Lozupone M, Logroscino G, Imbimbo BP. Nat Rev Neurol. 2019;15(2):73-88.
Increasing precision of clinical diagnosis of Alzheimer's disease using a combined algorithm incorporating clinical and novel biomarker data.
Sabbagh MN, Lue LF, Fayard D, Shi J. Neurol Ther. 2017;6(suppl 1):83-95.
Persistence of BAN2401-mediated amyloid reductions post-treatment: a preliminary comparison of amyloid status between the core phase of BAN2401-G000-201 and baseline of the open-label extension phase in subjects with early Alzheimer’s disease.
Swanson C, Zhang Y, Dhadda S, et al. Neurology. 2020;94(suppl 15):1330.
Potential new approaches for diagnosis of Alzheimer’s disease and related dementias.
Turner RS, Stubbs T, Davies DA, Albensi BC. Front Neurol. 2020;11:496.
What are the difficulties of implementing innovative pharmacy practice models in the care of patients with dementia?
Wimo A. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):1-4.
Economic burden of Alzheimer disease and managed care considerations.
Wong W. Am J Manag Care. 2020;26(suppl 8):S177-S183.
Clinical Practice Guidelines
The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease.
Albert MS, DeKosky ST, Dickson D, et al. Alzheimers Dement. 2011;7(3):270-279.
The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease.
McKhann GM, Knopman DS, Chertkow H, et al. Alzheimers Dement. 2011;7(3):263-269.
Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Petersen RC, Lopez O, Armstrong MJ, et al. Neurology. 2018;90(3):126-135.
